Erica Horodniceanu

[FDA Oncology @FDAOncology]

How can you recognize when online medical information is false or misleading? Sign up for a free virtual panel discussion, Cancer Misinformation: Truth or Consequences, to hear from experts including Sylvia Chou @Chou_sylvia @NCIBehaviors @theNCI
Sign up: https://t.co/4CG03vIbVx

[FDA Oncology @FDAOncology]

Register to attend FDA's 8th Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop on overall side effect impact, June 27 (virtual).
▶️ https://t.co/sCbuiCkf9K ◀️

#OCEOutcomes23 with @pkluetz @vishalbmd @EGHorod @Meena_PharmD
More Info https://t.co/IPluJDqETi

[FDA Oncology @FDAOncology]

Today, FDA issued a draft guidance to industry for developing plans to enroll more participants from underrepresented racial and ethnic populations in the US into clinical trials—expanding on previous guidances to improve #clinicaltrial #diversity. https://t.co/ubrAOwzjg3

[FDA Oncology @FDAOncology]

Join us May 10 for a #ConversationsOnCancer public panel discussion observing #WorldOvarianCancerDay. We'll explore personal perspectives from survivors, clinicians & patient advocates on the impact of ovarian cancer. #gyncsm
Registration: https://t.co/kiSxOpjkzV

[FDA Oncology @FDAOncology]

New! Read OCE's Annual Report on driving change in oncology product development for the benefit of patients with cancer. #OCEAnnualReport #EndCancerAsWeKnowIt
https://t.co/7IENp23BHX

[FDA Oncology @FDAOncology]

Join us March 10 to hear from @jillfeldman4  @LeeJonesMBA @AnnePCDI @EthanBasch1 @EGHorod Mirat Shah @rea_blakey @vishalbmd @realrickpazdur

#ConversationsOnCancer: More Isn't Always Better: Understanding Cancer Treatment Tolerability, 2pm ET. #OCEPFDD
https://t.co/ZtSWQDS5IX

[FDA Oncology @FDAOncology]

Have you registered yet for the next #ConversationsOnCancer? Join us March 10 for a free virtual public panel discussion - More Isn't Always Better: Understanding Cancer Treatment Tolerability, 2pm ET. #OCEPFDD #OCEProjectCommunity
https://t.co/ZtSWQE9H7x

[FDA Oncology @FDAOncology]

Register now: March 10 #ConversationsOnCancer: More Isn't Always Better: Understanding Cancer Treatment Tolerability, 2pm ET. With @jillfeldman4  @LeeJonesMBA @AnnePCDI @EthanBasch1 @EGHorod Mirat Shah @rea_blakey @vishalbmd @realrickpazdur #OCEPFDD
https://t.co/ZtSWQE9H7x

[Erica Horodniceanu @EGHorod]

Looking forward to COA-CCT 2021 next month!

[FDA Oncology @FDAOncology]

Have you registered yet? FDA public workshop-6th Annual Clinical Annual Clinical Outcome Assessment in Cancer Clinical Trials. Virtual sessions over 2 half days on July 21 (in PM) & July 23 (in AM) #OCEOutcomes21 @pkluetz @vishalbmd @EGHorod
https://t.co/NgDcLZfksm

[Media Affairs @FDAMedia]

Today, the FDA issued draft guidance to address which patient-reported outcomes to measure in cancer clinical trials. https://t.co/9DlLvoTpmd

[FDA Oncology @FDAOncology]

Registration is now open and free! FDA 6th Annual Clinical Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop-July 21 & 3,2021 (virtual) #OCEOutcomes21
@pkluetz @vishalbmd @EGHorod
https://t.co/hb1CjDRSVY

[Paul Kluetz @pkluetz]

Don't you wish you could access trial information on patient-reported side effects over time? How about for patients with no side effects at baseline? Meet @FDAOncology PROJECT PATIENT VOICE- a pilot website to communicate #PRO symptomatic side effects. https://t.co/N5M0GVVyWF